Zobrazeno 1 - 10
of 247
pro vyhledávání: '"Barbara A, Parker"'
Autor:
Michelle Rissling, Lianqi Liu, Shawn D. Youngstedt, Vera Trofimenko, Loki Natarajan, Ariel B. Neikrug, Neelum Jeste, Barbara A. Parker, Sonia Ancoli-Israel
Publikováno v:
Frontiers in Neuroscience, Vol 18 (2024)
Externí odkaz:
https://doaj.org/article/bc33d51a2dd64f89b57cf6b36ba425c5
Autor:
Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that zilovertamab was well
Externí odkaz:
https://doaj.org/article/0486bdf60d074a82b6fba59959ed172b
Autor:
Sheri J. Hartman, Rong W. Zablocki, Rowena M. Tam, Barton W. Palmer, Barbara A. Parker, Dorothy D. Sears, Tim A. Ahles, Loki Natarajan
Publikováno v:
Frontiers in Cognition, Vol 3 (2024)
IntroductionCancer related cognitive decline is a common long-term side effect of cancer and its treatments among breast cancer survivors. Physical activity is a modifiable risk factor related to cognitive decline. However, existing research lacks co
Externí odkaz:
https://doaj.org/article/bf585bea3c2f4f08bcb75b54afa2d65c
Autor:
Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf II, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/e6112c11579145ef905f2712d4ff134a
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which
Externí odkaz:
https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80
Autor:
Michelle Rissling, Lianqi Liu, Shawn D. Youngstedt, Vera Trofimenko, Loki Natarajan, Ariel B. Neikrug, Neelum Jeste, Barbara A. Parker, Sonia Ancoli-Israel
Publikováno v:
Frontiers in Neuroscience, Vol 16 (2022)
PurposeThe goal of this study was to examine whether daily increased morning light exposure would maintain or improve sleep and the circadian pattern of relatively more activity in the day and less during the night in women undergoing chemotherapy fo
Externí odkaz:
https://doaj.org/article/212152495109466a83065dd7f6adc51d
Autor:
Jennifer Maning, Katie A. McCrink, Celina M. Pollard, Victoria L. Desimine, Jennifer Ghandour, Arianna Perez, Natalie Cora, Krysten E. Ferraino, Barbara M. Parker, Ava R. Brill, Beatrix Aukszi, Anastasios Lymperopoulos
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 15, p 7767 (2021)
The authors wish to make the following correction to this paper [...]
Externí odkaz:
https://doaj.org/article/1655c0e4196042c5a8100dd9b28c330f
Autor:
Razelle Kurzrock, Barbara A. Parker, Kelly A. Shimabukuro, Richard B. Schwab, Paul T. Fanta, David E. Piccioni, Gregory A. Daniels, Maria Schwaederle
Despite the increased use of molecular diagnostics, the extent to which patients who have these tests harbor potentially actionable aberrations is unclear. We retrospectively reviewed 439 patients with diverse cancers, for whom next-generation sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::058e4b1109886d1a1ecbcc1c7fec407b
https://doi.org/10.1158/1535-7163.c.6536761.v1
https://doi.org/10.1158/1535-7163.c.6536761.v1
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation seque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38652e4f16dcdeda5f7bb5f11ff928f
https://doi.org/10.1158/1535-7163.c.6538405.v1
https://doi.org/10.1158/1535-7163.c.6538405.v1